BTIG Upgrades Progyny(PGNY.US) to Buy Rating, Announces Target Price $28
Progyny Analyst Ratings
BTIG Upgrades Progyny to Buy From Neutral, Price Target Is $28
Truist Financial Maintains Progyny(PGNY.US) With Hold Rating
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $23 to $34
Progyny Is Maintained at Hold by Canaccord Genuity
Progyny Analyst Ratings
Canaccord Genuity Maintains Hold on Progyny, Raises Price Target to $23
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $23 to $34
Truist Financial Maintains Progyny(PGNY.US) With Hold Rating
Jefferies Maintains Progyny(PGNY.US) With Buy Rating, Raises Target Price to $28
KeyBanc Maintains Progyny(PGNY.US) With Hold Rating
BofA Securities Maintains Progyny(PGNY.US) With Buy Rating, Raises Target Price to $30
Progyny Is Maintained at Buy by B of A Securities
Progyny Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY) and Axsome Therapeutics (AXSM)
BofA Securities Maintains Progyny(PGNY.US) With Buy Rating, Raises Target Price to $25
Truist Financial Maintains Progyny(PGNY.US) With Hold Rating, Announces Target Price $24
Progyny's Strategic Acquisition Prompts Hold Rating Amid Short-Term Growth Uncertainty
Truist Financial Maintains Progyny(PGNY.US) With Hold Rating